ATE476663T1 - Spiegel der müllerschen inhibierenden substanz und ovarialreaktion - Google Patents

Spiegel der müllerschen inhibierenden substanz und ovarialreaktion

Info

Publication number
ATE476663T1
ATE476663T1 AT02759420T AT02759420T ATE476663T1 AT E476663 T1 ATE476663 T1 AT E476663T1 AT 02759420 T AT02759420 T AT 02759420T AT 02759420 T AT02759420 T AT 02759420T AT E476663 T1 ATE476663 T1 AT E476663T1
Authority
AT
Austria
Prior art keywords
response
mis
ovarian
fertility
treatment
Prior art date
Application number
AT02759420T
Other languages
English (en)
Inventor
David Seifer
David Maclaughlin
Original Assignee
Univ New Jersey Med
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23216148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476663(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New Jersey Med, Gen Hospital Corp filed Critical Univ New Jersey Med
Application granted granted Critical
Publication of ATE476663T1 publication Critical patent/ATE476663T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02759420T 2001-08-20 2002-08-20 Spiegel der müllerschen inhibierenden substanz und ovarialreaktion ATE476663T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31354501P 2001-08-20 2001-08-20
PCT/US2002/026605 WO2003016514A1 (en) 2001-08-20 2002-08-20 Mullerian inhibiting substance levels and ovarian response

Publications (1)

Publication Number Publication Date
ATE476663T1 true ATE476663T1 (de) 2010-08-15

Family

ID=23216148

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759420T ATE476663T1 (de) 2001-08-20 2002-08-20 Spiegel der müllerschen inhibierenden substanz und ovarialreaktion

Country Status (14)

Country Link
US (2) US7241577B2 (de)
EP (1) EP1419239B1 (de)
JP (1) JP4508639B2 (de)
AT (1) ATE476663T1 (de)
AU (1) AU2002324756B2 (de)
CA (1) CA2457918C (de)
DE (1) DE60237211D1 (de)
DK (1) DK1419239T3 (de)
EA (1) EA012444B1 (de)
ES (1) ES2350090T3 (de)
IL (2) IL160254A0 (de)
NZ (1) NZ547233A (de)
PT (1) PT1419239E (de)
WO (1) WO2003016514A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
ATE478336T1 (de) * 2005-05-24 2010-09-15 Beckman Coulter Inc Immunologische assays und antikörper für das anti-müller-hormon
EP2199799A1 (de) 2008-12-19 2010-06-23 Institut National de la Recherche Agronomique Verfahren zur Auswahl von Tieren mit einer hohen Embryoerzeugung
EP3336552A3 (de) 2010-11-29 2018-07-25 Mote Marine Laboratory, Inc. Bestimmung der geschlechtsmerkmale von fischen mittels peptidhormonen
US20130224771A1 (en) * 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
HK1222331A1 (zh) 2013-03-12 2017-06-30 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
EP3046582A4 (de) 2013-09-20 2017-05-10 The General Hospital Corporation Verwendung von modifizierten müllerschen hemmstoff (mis)-proteinen zur behandlung von neurodegenerativen erkrankungen
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
RU2612839C1 (ru) * 2015-10-15 2017-03-13 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ прогноза развития синдрома гиперстимуляции яичников при применении вспомогательных репродуктивных технологий
US10175252B2 (en) 2016-02-04 2019-01-08 American Infertility Of New York, P.C. Diagnosis, and anti-mullerian hormone (AMH) administration for treatment, of infertility for good-, intermediate- and poor-prognosis patients for in vitro fertilization in view of logistic regression models
WO2018112168A1 (en) 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
CN120446363B (zh) * 2025-07-09 2025-09-23 北京大学第三医院（北京大学第三临床医学院） 一种用于卵巢储备功能减退诊断的血液生物标志物、试剂盒及其应用
CN120427812B (zh) * 2025-07-09 2025-10-10 北京大学第三医院（北京大学第三临床医学院） 一种用于卵巢储备功能减退诊断的尿液生物标志物、试剂盒及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792601A (en) * 1982-03-01 1988-12-20 The General Hospital Corporation Monoclonal antibody to mullerian inhibiting substance
US5310880A (en) * 1991-04-12 1994-05-10 The General Hospital Corporation Purification of Mullerian inhibiting substance
AU3920693A (en) * 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
EP1074265A1 (de) * 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Verwendung von AMH und/oder AMH Agonisten und/oder AMH Antagonisten zur langfristigen Regulierung von weiblicher Fertilität

Also Published As

Publication number Publication date
EP1419239A4 (de) 2006-01-11
JP4508639B2 (ja) 2010-07-21
WO2003016514A1 (en) 2003-02-27
CA2457918C (en) 2013-11-26
ES2350090T3 (es) 2011-01-18
CA2457918A1 (en) 2003-02-27
PT1419239E (pt) 2010-11-08
EA200400333A1 (ru) 2004-10-28
EP1419239B1 (de) 2010-08-04
NZ547233A (en) 2008-11-28
DK1419239T3 (da) 2010-11-22
US20070248544A1 (en) 2007-10-25
AU2002324756B2 (en) 2008-08-07
DE60237211D1 (de) 2010-09-16
IL160254A0 (en) 2004-07-25
US7427486B2 (en) 2008-09-23
EA012444B1 (ru) 2009-10-30
US7241577B2 (en) 2007-07-10
IL160254A (en) 2010-04-15
HK1066243A1 (en) 2005-03-18
EP1419239A1 (de) 2004-05-19
US20030124620A1 (en) 2003-07-03
JP2005502862A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
DE60237211D1 (de) Spiegel der müllerschen inhibierenden substanz und ovarialreaktion
Mirmirani et al. Short course of oral cyclosporine in lichen planopilaris
EP1467757A4 (de) Verwendung von antikörpern gegen das muc18-antigen
DK0882021T3 (da) Nye phenanthridiner
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
EP1253929A4 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingte erkrankungen
EP1242060A4 (de) Behandlung von krankheiten mit metastasenbildung
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
TR200102977T2 (tr) Yeni tedavi yöntemi.
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
TR200002626T2 (tr) Terkip
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
BR0110759A (pt) Métodos para modular o crescimento de uma célula, e para o tratamento e/ ou profilaxia de uma condição distinguida pelo crescimento celular aberrante, indesejável ou de outro modo não apropriado em um mamìfero, uso de um agente capaz de modular a atividade funcional de esfingosina quinase, composição farmacêutica, e, método de diagnose de uma condição, ou uma predisposição ou resistência a uma condição, distinguida pelo crescimento celular aberrante, indesejável, ou de outro modo não apropriado em um mamìfero
DE60232244D1 (de) Nachweis und behandlung von prostatakrebs
WO2002088181A3 (en) Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
NO20002218D0 (no) Anvendelse av mirtazepin for behandling av søvnapne
DE69722809D1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
ATE260111T1 (de) Mittel zur behandlung von autoimmunkrankheiten
PT1121108E (pt) Nova utilizacao terapeutica de compostos com actividade beta-3-agonista
TR200003084T2 (tr) Paroxetine askorbat

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1419239

Country of ref document: EP